Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 17;3(10):1181–1191. doi: 10.1038/s43018-022-00439-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a, Variants detected by Signatera assay of baseline and progression ctDNA samples plotted by VAF. Dashed lines represent fivefold difference cutoffs, n = 14 patients. b, pWES-identified indels (n = 18 patients) at baseline and progression. c, SNVs identified by pWES at baseline and progression (n = 18 patients). d, Deleterious SNVs enriched fivefold in progression samples (n = 6 patients) from responders (decrease of >20% in SLD) compared to baseline. Variants identified in tumor WES are shown (an anterisk indicates insufficient sample for tumor WES). e, ctDNA SNV counts are significantly increased in progression samples compared to control samples (n = 18 patients), whereas there is no significant difference in indel counts (two-way ANOVA with Tukey’s correction, *P = 0.033; median indicated by horizontal line). NS, not significant. f, scarHRD was used to calculate ctHRD score from baseline pWES and correlated with time to progression in days. The correlation coefficient (r) and two-sided P value were calculated with Pearson’s method and are depicted as a dashed line. n = 12 patients.

Source data